Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 97 of the 98 references it cites were found in a registry or an index; none of the 51 sources its claims cite is checked for support yet.

Pathological mutations in the phospholamban cytoplasmic region affect its topology and dynamics modulating the extent of SERCA inhibition

Open access
Weber, Daniel K., Reddy, U. Venkateswara, Robia, Seth L., Veglia, Gianluigi · 2024 · Biochimica et Biophysica Acta (BBA) - Biomembranes

Abstract

Phospholamban (PLN) is a 52 amino acid regulin that allosterically modulates the activity of the sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) in the heart muscle. In its unphosphorylated form, PLN binds SERCA within its transmembrane (TM) domains, approximately 20 Å away from the Ca2+ binding site, reducing SERCA’s apparent Ca2+ affinity (pKCa) and decreasing cardiac contractility. During the enzymatic cycle, the inhibitory TM domain of PLN remains anchored to SERCA, whereas its cytoplasmic region transiently binds the ATPase’s headpiece. Phosphorylation of PLN at Ser16 by protein kinase A increases the affinity of its cytoplasmic domain to SERCA, weakening the TM interactions with the ATPase, reversing its inhibitory function, and augmenting muscle contractility. How the structural changes caused by pathological mutations in the PLN cytoplasmic region are transmitted to its inhibitory TM domain is still unclear. Using solid-state NMR spectroscopy and activity assays, we analyzed structural and functional effects of a series of mutations and their phosphorylated forms located in the PLN cytoplasmic region and linked to dilated cardiomyopathy. We found that these missense mutations affect the overall topology and dynamics of PLN and ultimately modulate its inhibitory potency. Also, the changes in the TM tilt angle and cytoplasmic dynamics of PLN caused by these mutations correlate well with the extent of SERCA inhibition. Our study unveils new molecular determinants for designing variants of PLN that outcompete endogenous PLN to regulate SERCA in a tunable manner.

Overview

CoChat Summary

TL;DR

Using solid-state NMR and activity assays, the authors show that dilated cardiomyopathy-linked mutations in the phospholamban cytoplasmic domain alter PLN topology and dynamics, and that these changes correlate with the extent of SERCA inhibition. TM tilt angle and cytoplasmic dynamics emerge as structural determinants of PLN inhibitory potency.

Key findings

  • DCM mutations in PLN domain Ia (R9C, R9H, R9L, R25C) change PLN topology and dynamics. For wild-type PLN, the inhibitory orientation has θ = 37.2 ± 0.8° and ρL31 = 198 ± 4°; S16 phosphorylation shifts it to a non-inhibitory state with θ = 35 ± 1° and ρL31 = 200 ± 3°, while RlpCP/CP increases from 20 ± 2% to 49 ± 2%.
  • PLNR9H, PLNR25C, PLNR9C, and PLNR9L show altered tilt/rotation and dynamics: PLNR9H shifts from θ = 37 ± 1° to 35.4 ± 0.9° upon phosphorylation; PLNR25C shifts from θ = 39 ± 1° to 36 ± 1°; PLNR9C has θ = 38 ± 1°; PLNR9L has θ = 39 ± 1°. RlpCP/CP values were 179 ± 24% → 186 ± 19% for R9H, 9 ± 1% → 32 ± 4% for R25C, 24 ± 2% for R9C, and 7 ± 1% for R9L.
  • In activity assays, pPLNR9H, pPLNR9L, and pPLNR25C had roughly identical ATPase activities and ΔpKCa values; the exception was pPLNR9C, whose S16 phosphorylation did not completely reverse SERCA inhibition.
  • ΔpKCa correlated with RlpCP/CP with R² = 0.54 (two-tailed p = 0.051) except for PLNR9H and pPLNR9H outliers, and correlated better with TM tilt angle with R² = 0.62 (two-tailed p = 0.012), indicating larger tilt angles are more inhibitory.

Methods

  • Oriented-sample solid-state NMR used a cysteine-null monomeric PLN background (C36A, C41F, C46A) with R9C, R9H, R9L, R25C, or R14del substitutions; proteins were expressed in E. coli, purified, phosphorylated with PKA, and verified by MALDI-MS. Samples were reconstituted in magnetically oriented DMPC:POPC/DHPC bicelles (q = 4.0, 5 mM Yb³⁺, pH 4.2, 27 °C) and analyzed on a 700 MHz Varian VNMRS using SE-SAMPI4, 1D CP, and low-power CP experiments; PISA-SPARKY fits yielded tilt, azimuthal, and order parameters, and RlpCP/CP ratios.
  • SERCA activity assays used SERCA1a purified from rabbit skeletal muscle, co-reconstituted with PLN or mutants at a 5:1 molar ratio in DOPC:DOPE (4:1; 2500:1 lipid:SERCA). Enzyme-coupled NADH assays were run at pCa 8.0–5.0, and Hill fits extracted Vmax, Vmin, and pKCa; assays were done in triplicate.

Limitations

  • The paper states that it used the AFA monomeric PLN species to avoid monomer–pentamer equilibrium complications, but notes that AFA is a slight gain-of-function mutant with limitations as a functional model; future work will analyze monomer–pentamer equilibrium.
  • The paper states that PLNR9C bicelle preparations were unstable, and phosphorylation of PLNR9C and PLNR9L increased aggregation, preventing well-aligned bicelles for NMR analysis.
  • Evident from the text: the correlations are moderate (R² = 0.54 and 0.62) and R9H/pR9H are outliers; functional assays used skeletal-muscle SERCA1a rather than cardiac SERCA2a, and R14del appears in Methods but no results are reported for it.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.bbamem.2024.184370

Cites

97 of 97 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 0 Not valid · 32 Not checked · 51 Own results and interpretations

42 more claims

Create a free account to see all 83 claims and to verify the 51 references still open.

See all claims — free account
  • It may state two separate claims as one. 26
  • Probably not a substantial claim. 18

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 98 references

Research works printed but not linked: 1

  1. Weber, 2021, Structural basis for allosteric control of the SERCA-phospholamban membrane complex by Ca2+ and cAMP-dependent phosphorylation, Elife, 10, 10.7554/elife.66226 · doi:10.7554/elife.66226

Cited by

See all 8

Metadata

Authors
Weber, D. K., Reddy, U. V., Robia, S. L., & Veglia, G.
Affiliations
  • University of Minnesota (US)
  • Loyola University Chicago (US)
Corresponding author
Veglia, Gianluigi
Venue
Biochimica et Biophysica Acta (BBA) - Biomembranes
Publisher
Elsevier BV
Published
2024-10
Volume
1866
Issue
7
Pages
184370
ISSN
0005-2736 (ISSN-L)
OpenAlex
W4400478201
Cited by
8
References
98
Citations by year
2026: 3 · 2025: 4
FWCI
1.85
Type
journal article
Language
en
Open access
Locations
  • Biochimica et Biophysica Acta (BBA) - Biomembranes (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
Funders
  • National Institutes of Health (HL144130)
  • AHA (19POST34420009)
  • NHLBI (HL143816, HL092321)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
Keywords
phospholamban, SERCA, dilated cardiomyopathy, missense mutations, cytoplasmic domain, transmembrane domain, protein topology, protein dynamics, allosteric regulation, protein phosphorylation, Ser16 phosphorylation, protein kinase A, calcium affinity, cardiac contractility
MeSH terms
Phospholamban, Animals, Binding Sites, Calcium, Calcium-Binding Proteins, Cytoplasm, Humans, Mutation, Phosphorylation, Protein Binding, Sarcoplasmic Reticulum Calcium-Transporting ATPases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pathological mutations in the phospholamban cytoplasmic region affect its topology and dynamics modulating the extent of SERCA inhibition. https://app.cochat.ai/papers/10.1016/j.bbamem.2024.184370
The paper
Weber, D. K., Reddy, U. V., Robia, S. L., & Veglia, G. (2024). Pathological mutations in the phospholamban cytoplasmic region affect its topology and dynamics modulating the extent of SERCA inhibition. Biochimica et Biophysica Acta (BBA) - Biomembranes. https://doi.org/10.1016/j.bbamem.2024.184370

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.